NeuraLight develops a software platform that utilizes computer vision and machine learning to analyze eye movements, providing objective measurements for central nervous system diseases. This technology enables researchers to differentiate between healthy subjects and patients, stratify subgroups, and monitor disease progression in clinical trials.
Funding
$30.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
KDFounders
Product
Problem
Central nervous system (CNS) diseases lack objective and reliable measurement tools for diagnosis, stratification, and monitoring of disease progression. Traditional methods rely on subjective clinical assessments, limiting the ability to accurately track treatment response and develop effective therapies.
Solution
NeuraLight offers a software platform that uses computer vision and machine learning to analyze eye movements, providing objective oculometric measures for CNS diseases. The platform captures and quantifies various eye movement parameters, enabling researchers to differentiate between healthy subjects and patients, stratify patient subgroups, and monitor disease progression in clinical trials. By providing a more precise and reliable measurement tool, NeuraLight aims to accelerate CNS drug development and improve patient outcomes.
Target Audience
The primary target audience includes clinical researchers and pharmaceutical companies involved in CNS drug development, as well as medical centers conducting clinical trials for CNS diseases.
Features
- Computer vision algorithms for precise tracking and analysis of eye movements.
- Machine learning models to extract meaningful oculometric measures from eye-tracking data.
- Objective measurements that correlate with traditional disability assessments in Multiple Sclerosis.
- Platform designed for easy implementation in clinical practice.
- Integration with clinical workflows for seamless data collection and analysis.
- Support for various CNS diseases, including Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease, and Frontotemporal Degeneration.